In keeping with prior work from our group and others on TKI type switching in fusion‐positive tumours,31, 60, 61, 62, 63, 64, 65 we also showed that the METG1090A mutation, while conferring resistance to type I MET inhibitors, does not affect the binding properties of type II TKIs. The gene discussed is MET; the disease is neoplasm.